A clinical trial (NCT05013216) is underway to assess the efficacy of a GNAS and KRAS-targeting peptide vaccine in preventing pancreatic cancer in high-risk individuals, with results expected in 2026. 12. This evidence concerns the gene KRAS and pancreatic neoplasm.